SCHEMBL6340331

SCHEMBL6340331

COC(=O)c1ccccc1NC(=O)Cc1ccc(Oc2ccc(OCc3cccc(NC(=O)OC(C)(C)C)c3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 2/20 0.51
ALDH1A1 P00352 4/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPK10 P53779 2/20 0.44
NLRP3 Q96P20 3/20 0.44
RXFP1 Q9HBX9 2/20 0.43
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 3/20 0.42
USP2 O75604 1/20 0.42
HPGD P15428 2/20 0.42
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MAPK8 P45983 1/20 0.42
MAPK9 P45984 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6340171 0.91 SMN1; SMN2 (0.49) SIRT2ALDH1A1TSHRHSD17B10MAPK10
SCHEMBL6340801 0.88 NPC1 (0.48) SIRT2ALDH1A1TSHRHSD17B10MAPK10
SCHEMBL6338576 0.86 PPARD (0.55) SIRT2ALDH1A1RXFP1SIRT1SIRT3
SCHEMBL6338768 0.85 ALDH1A1 (0.47) ALDH1A1TSHRHSD17B10MAPK10KMT2A
SCHEMBL6349020 0.83 ALDH1A1 (0.60) SIRT2ALDH1A1TSHRHSD17B10MAPK10
SCHEMBL6341460 0.81 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10MAPK10KMT2A
Benzoic Acid SCHEMBL8041305 0.78 ALDH1A1 (0.55) ALDH1A1TSHRHSD17B10MAPK10KMT2A
SCHEMBL6340720 0.78 ALDH1A1 (0.52) ALDH1A1TSHRHSD17B10MAPK10KMT2A
SCHEMBL8041179 0.77 ALDH1A1 (0.52) ALDH1A1TSHRHSD17B10MAPK10KMT2A
SCHEMBL12533268 0.77 SIRT2 (0.60) SIRT2SIRT1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 SIRT2 3359/4885ALDH1A1 250/4885TSHR 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.